ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United States
ARS Pharmaceuticals, Inc. (SPRY)
Company Research
Source: GlobeNewswire
Agreement leverages ALK’s global footprint in developing and commercializing innovative allergy products ARS Pharma to receive an upfront cash payment of $145 million, with total deal consideration of up to $465 million plus double-digit royalties on net sales ARS Pharma retains all U.S. rights, and existing partnerships in Japan, China, Australia and New Zealand with Alfresa, Pediatrix and CSL, respectively SAN DIEGO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced a licensing agreement with ALK-Abelló A/S (“ALK”, Nasdaq: ALK B), that provides ALK exclusive rights to commercialize neffy® (epinephrine nasal spray) (trade name EURneffy® in Europe), the first and only needle-free emergency treatment for Type I allergic reactions including anaphylaxis, in Europe, Canada
Show less
Read more
Impact Snapshot
Event Time:
SPRY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SPRY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SPRY alerts
High impacting ARS Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
SPRY
News
- ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $40.00 price target on the stock.MarketBeat
- ARS Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare ConferenceGlobeNewswire
- ARS Pharmaceuticals Launches neffyinSchools Program Providing Free Life-Saving Needle-Free Epinephrine For Emergency Use to Eligible K-12 SchoolsGlobeNewswire
- ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) had its price target raised by analysts at Raymond James from $26.00 to $28.00. They now have a "strong-buy" rating on the stock.MarketBeat
- ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) had its price target raised by analysts at Leerink Partners from $26.00 to $27.00. They now have an "outperform" rating on the stock.MarketBeat
SPRY
Earnings
- 11/13/24 - Miss
SPRY
Sec Filings
- 2/4/25 - Form 4
- 2/3/25 - Form 144
- 1/31/25 - Form S-3ASR
- SPRY's page on the SEC website